FDA panel backs safety
updates for AstraZeneca, Takeda drugs
Send a link to a friend
[April 15, 2015] By
Toni Clarke
WASHINGTON (Reuters) - AstraZeneca Plc's
diabetes drug Onglyza and Takeda Pharmaceutical Co.'s rival product
Nesina should carry information about the risk of heart failure, an
advisory committee to the U.S. Food and Drug Administration said on
Tuesday.
|
Heart failure is a condition in which the heart cannot pump enough
blood to meet the body's needs. It can be caused by coronary artery
disease, high blood pressure, diabetes or obesity, according to the
Mayo Clinic.
The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's
Nesina. The drugs belong to a class known as DPP-4 inhibitors which
also includes Merck & Co.'s Januvia. Januvia data from a trial known
as TECOS will be presented at a scientific meeting in June.
The studies were requested by the FDA as part of a broader
investigation into the safety of diabetes drugs. In December 2008,
the agency issued guidance requiring companies to conduct studies to
show the drugs did not increase cardiovascular risk.
![](http://archives.lincolndailynews.com/2015/Apr/15/images/ads/current/napa_bch1-3108.png)
The panel found that neither Onglyza nor Nesina increased the risk
of cardiovascular death, stroke or heart attack. But data showed a
statistically significant increase in the risk of heart failure with
Onglyza and an increased risk with Nesina that did not reach
statistical significance.
Some panelists said that even though the heart failure risk seen
with Nesina was modest, they suspect the risk will turn out to be a
DPP-4 class effect and therefore worth including.
The panel did not recommend any restrictions on prescribing the
drugs. AstraZeneca's U.S. shares rose 3.2 percent. Takeda's shares
closed down 0.67 percent before the vote was announced. Merck's
shares rose 1.8 percent.
"Given the absence of a serious safety issue for either Onglyza or
Takeda's Nesina suggests that, barring an overtly negative signal in
TECOS, growth of the DPP-4 class is likely to continue without a
meaningful change in current prescribing trends," Leerink analyst
Seamus Fernandez said in a research note.
[to top of second column] |
![](../images/ads/current/Symphony_122313.png)
A preliminary FDA review of Onglyza published on Friday found an
increase in the rate of death from all causes. Panel members said
they were moderately concerned about the signal but said their
concern was muted by the fact that the causes of death were varied
and lacked any common theme.
Onglyza, known also as saxagliptin, was approved in 2009. Nesina, or
alogliptin, was approved in 2013. The FDA is not obliged to follow
the advice of its advisory panels but typically does so.
(Reporting by Toni Clarke; Editing by Will Dunham and Andrew Hay)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2015/Apr/15/images/ads/current/garage_sale_bch.png)
![](http://archives.lincolndailynews.com/2015/Apr/15/images/ads/current/graue_2015_silverado_031615.png) |